Investigation and management of subfertility

Layla Thurston, Ali Abbara, Waljit S Dhillon[✉]

Section of Investigative Medicine, Division of Diabetes and Endocrinology, Imperial College London, London, UK

Correspondence to

Professor
Waljit S Dhillon, Imperial College London, London SW7 2AZ, UK;
w.dhillon@imperial.ac.uk

Received 2 January 2019

Revised 24 June 2019

Accepted 25 June 2019

Published Online First

11 July 2019

ABSTRACT

Subfertility affects one in seven couples and is defined as the inability to conceive after 1 year of regular unprotected intercourse. This article describes the initial clinical evaluation and investigation to guide diagnosis and management. The primary assessment of subfertility is to establish the presence of ovulation, normal uterine cavity and patent fallopian tubes in women, and normal semen parameters in men. Ovulation is supported by a history of regular menstrual cycles (21–35 days) and confirmed by a serum progesterone >30 nmol/L during the luteal phase of the menstrual cycle. Common causes of anovulation include polycystic ovary syndrome (PCOS), hypothalamic amenorrhoea (HA) and premature ovarian insufficiency (POI). Tubal patency is assessed by hysterosalpingography, hystero-contrast sonography, or more invasively by laparoscopy and dye test. The presence of clinical or biochemical hyperandrogenism, serum gonadotrophins (luteinising hormone/follicle stimulating hormone) / oestradiol, pelvic ultrasound to assess ovarian morphology / antral follicle count, can help establish the cause of anovulation. Ovulation can be restored in women with PCOS using letrozole (an aromatase inhibitor), clomifene citrate (an oestrogen antagonist) or exogenous gonadotrophin administration. If available, pulsatile gonadotrophin releasing hormone therapy is the preferred option for restoring ovulation in HA. Spermatogenesis can be induced in men with hypogonadotrophic hypogonadism with exogenous gonadotrophins. Unexplained subfertility can be treated with in vitro fertilisation after 2 years of trying to conceive. Involuntary childlessness is associated with significant psychological morbidity; hence, expert assessment and prompt treatment are necessary to support such couples.

BACKGROUND

Subfertility is defined as the inability to conceive after 1 year of regular unprotected intercourse and it affects one in seven couples in the UK.¹ Subfertility is not an absolute state and its definition simply reflects the likelihood of conception with time; 84% of couples will conceive within 1 year of trying and 92% within 2 years.² A couple who have not conceived after 1 year of regular unprotected sexual intercourse should be offered further clinical assessment. Owing to the prognostic impact of the female partner's age, National Institute for Health and Care Excellence (NICE) recommends that referral should be made sooner if the female partner is aged ≥36 years, or if either partner have a known cause of subfertility that would make further attempts to conceive without assistance futile, for example, amenorrhoea (absent periods), previous salpingectomy (removal of the fallopian tubes following

previous ectopic pregnancy), azoospermia (absent sperm) or predisposing factors for subfertility.¹ In the UK, the most common causes of subfertility are 'male factor' subfertility (30%), ovulatory dysfunction (25%), tubal (20%) and uterine/peritoneal disorders (10%); however, 25% remain 'unexplained' following standard investigations.¹

It is preferred that couples are reviewed in the consultation together as both partners are impacted by the investigation and treatment of subfertility.¹ Initial assessments can be commenced in primary care; however, NICE recommends that couples have access to a specialist service as this improves effectiveness of management and patient satisfaction.¹

HISTORY

For both partners, a history of prior conception establishes if subfertility is primary (no previous conception) or secondary (previous conception). Other important aspects of the history include the ages of both partners, the duration of 'trying to conceive', the frequency of sexual intercourse, medication history (including over-the-counter medications), alcohol, smoking and illicit drug use (see table 1). If pubertal development was incomplete, further history should include parental height, family history of disordered pubertal development, or anosmia that could suggest Kallmann syndrome.³

History in the female partner should also include the following: a full menstrual history (including average cycle length, number of menses per year and age of menarche) to establish the presence of oligomenorrhoea (cycle length >35 days or <8 cycles per year) or amenorrhoea (≥3 months without menses or <3 menses per year). Regular menstrual cycles usually indicate ovulatory cycles in a young woman without hyperandrogenism. Symptoms of hyperandrogenism (eg, hirsutism, acne) are consistent with polycystic ovary syndrome (PCOS).⁴ Weight gain causing insulin resistance and a family history can increase the likelihood of PCOS.⁴ Duration of hirsutism is important; a sudden severe onset of hyperandrogenism should prompt consideration of an androgen secreting tumour. Congenital adrenal hyperplasia (CAH) can be partial and is frequently underdiagnosed; thus, CAH should also be excluded in women with hyperandrogenism. Hypothalamic amenorrhoea (HA) is caused by a combination of low body weight, psychological stress, excessive exercise and genetic predisposition. Thus, assessment of change in body weight, and in particular whether energy expenditure through exercise is likely to exceed energy intake from diet, as well as family history of menarche and menstrual disturbance, can help assess the likelihood of HA. A history of headaches, galactorrhoea or visual field disturbance in combination with oligo/amenorrhoea

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Thurston L, Abbara A, Dhillon WS. *J Clin Pathol* 2019;**72**:579–587.

Table 1 History, examination and investigation of female and male subfertility

	Female	Male	Both
History	Ovulatory cycles: Average menstrual cycle length (usually within ± 2 days for most women), number of menses per year, contraception history Hypothalamic amenorrhoea: Weight loss, excessive exercise, psychological stress, family history PCOS/CAH: Hirsutism, acne, oligomenorrhoea Endometriosis: Dyspareunia, dysmenorrhoea, cyclical pelvic pain PID Pelvic pain, discharge, STIs	Testosterone deficiency: Libido, potency/erectile dysfunction, shaving frequency, gynaecomastia. Risk factors for testicular dysfunction: History of mumps/orchitis History of STIs Trauma Previous oncological treatments	General questions: Duration of trying to conceive Fecundity, frequency of sexual intercourse, pubertal milestones Medical history, medications, alcohol, smoking, illicit drug use Prolactinoma: Headaches, galactorrhoea, visual field impairment Kallmann syndrome: Anosmia, incomplete pubertal development. Can be associated with other features depending on specific mutation, for example, hearing impairment, renal agenesis, synkinesia
Examination	Signs of hyperandrogenism: Ferriman-Gallwey score for hirsutism. Acne. Pelvic examination	Testicular volume with Prader orchidometer. Epididymal hardness/thickening Presence of vas deferens	Secondary sexual characteristics BMI
Investigations			
Male factor		Semen analysis	
Microbiology	Rubella serology		Chlamydia swab/urine test
Bloods	Mid-luteal progesterone level Oligomenorrhoeic/anoovulatory: FSH, LH, oestradiol, SHBG, testosterone, prolactin, follicular phase 17-OHP, serum AMH.	Pre-10 am fasting testosterone FSH, LH, SHBG, albumin Iron studies for haemochromatosis	If undergoing ART: HIV, hepatitis B and C Thalassemia/sickle cell
Imaging	TVUS, HyCoSy, HSG to assess tubal patency and uterine cavity	Scrotal US/Doppler for varicocele or obstructive causes	

AMH, anti-Müllerian hormone; ART, assisted reproductive treatment; BMI, body mass index; CAH, congenital adrenal hyperplasia; FSH, follicle stimulating hormone; HA, hypothalamic amenorrhoea; HIV, human immunodeficiency virus; HSG, hysterosalpingography; HyCoSy, hystero-contrast sonography; LH, luteinising hormone; 17-OHP 17, hydroxyprogesterone; PCOS, polycystic ovary syndrome; PID, pelvic inflammatory disease; SHBG, sex hormone binding globulin; STIs, sexually transmitted infections; TVUS, transvaginal ultrasound; US, ultrasound.

could indicate a raised prolactin level due to pituitary pathology. Dyspareunia (pain during intercourse), dysmenorrhoea (painful menses) or pelvic pain could indicate endometriosis.

History in the male partner should encompass symptoms of testosterone insufficiency, for example, libido, potency, frequency of shaving, gynaecomastia and past medical history of risk factors for testicular dysfunction from infection (mumps orchitis or sexually transmitted infections), previous cryptorchidism, trauma or previous oncological treatments (see [table 1](#)).

EXAMINATION

Body mass index (BMI) should be evaluated to assess the likelihood of HA, PCOS or obesity-related hypogonadism. The presence of secondary sexual characteristics should be assessed in both partners. Visual fields should be examined in patients with headaches, galactorrhoea or other symptoms consistent with pituitary dysfunction. Features of hyperandrogenism, including hirsutism assessed by the modified Ferriman Gallwey score,⁵ and pelvic examination should be performed in women. In men, assessment of testicular volume with a Prader orchidometer is a key examination to determine whether normal pubertal development has occurred. Obstructive azoospermia may be suggested by at least one testis > 15 mL, enlarged or hardened epididymis, or nodularity of the epididymis or vas deferens. Gynaecomastia (presence of firm glandular tissue behind the nipple) and body hair distribution can indicate low testosterone levels.

INVESTIGATIONS

Semen analysis

Semen analysis is essential in the diagnostic work-up of all subfertile couples. It should be performed after 2–5 days of sexual abstinence (see [table 2](#) for normal values). The results can be highly variable and thus usually at least two samples are required to confirm an abnormal result. A mildly abnormal result should be repeated in 12 weeks to allow time for a further cycle of spermatogenesis; however, a severe abnormality, for example, azoospermia (absent sperm) should be repeated sooner. Abnormal values may prompt more detailed assessments of sperm function in a specialist centre. Often abnormalities may occur together (see [table 2](#)); if oligozoospermia (low concentration), asthenozoospermia (low motility) and teratozoospermia (increased abnormal morphology) co-aggregate in the same patient, this is described as oligo-astheno-teratozoospermia (OAT). Urine microscopy and culture should be assessed in men with leukocytospermia. Post-ejaculatory urine samples can be used to assess for retrograde ejaculation. Sperm antibodies in semen do not need to be measured routinely.¹

Biochemistry

Confirmation of ovulation in women

Almost all young women with a history of regular menstrual cycles are ovulatory; however, only 60% of women with hyperandrogenism and regular cycles are ovulatory. Thus, a serum

Table 2 Semen analysis reference values (WHO criteria)⁵⁷

	Normal value	Description of abnormality	Further specialist tests to be considered if abnormal
Semen volume	≥1.5 mL	Oligospermia	Consider obstructive causes/CBAVD-CFTR mutation Aspermia (no ejaculate)—assess prostate and for retrograde ejaculation with post-ejaculatory urine analysis
pH	≥7.2		
Sperm concentration	≥15 million spermatozoa per mL	Oligozoospermia <15 million Severe oligozoospermia <5 million Azoospermia (no sperm)	<i>If <10 million:</i> Endocrine evaluation (FSH / LH / 10 am fasting testosterone) / clinical examination / US Doppler for varicocele <i>If <5 million:</i> Chromosomal analysis/PCR for Y microdeletions
Total motility	≥40% motile	Asthenozoospermia	Anti-sperm antibody Sperm viability and membrane test
Vitality	≥58% live spermatozoa		
Morphology	≥4% normal forms	Teratozoospermia	Sperm penetration assay

CBAVD, congenital bilateral absence of the vas deferens; CFTR, cystic fibrosis transmembrane conductance regulator; FSH, follicle stimulating hormone; LH, luteinising hormone; US, ultrasound.

progesterone in the mid-luteal (7 days after ovulation, or 7 days before predicted menses) should be measured as evidence of ovulation. A value >30 nmol/L is commonly used to confirm ovulation; however, lower values may also indicate ovulation has occurred. A single serum progesterone level ≥15.9 nmol/L has a sensitivity of 89.6% and a specificity of 98.4% for detecting ovulation.⁶

Anovulatory women

In all patients with amenorrhoea, the most common cause is pregnancy and thus this should be excluded prior to further evaluation. PCOS is often associated with increased gonadotrophin releasing hormone (GnRH) pulsatility (raised serum luteinising hormone (LH)), whereas HA or hyperprolactinaemia is associated with reduced GnRH pulsatility (low serum LH).⁷ Serum oestradiol is often preserved in women with PCOS, but can be reduced in women with HA, hyperprolactinaemia or premature ovarian insufficiency (POI). Raised androgens could indicate PCOS or CAH. A low serum sex hormone binding globulin (SHBG), which increases free androgen levels, can occur in overweight or insulin-resistant women and thus can also be a feature of PCOS. A 17-hydroxy-progesterone level should be assessed during the follicular phase in women with hyperandrogenism and if not low, referred to an endocrinology specialist service for further assessment with a stimulated level in a short Synacthen test.

Serum prolactin levels exhibit a diurnal variation with highest values typically during sleep; however, levels are similar during waking hours and prolactin can be measured at any time of day.⁸ A mildly elevated serum prolactin level (500–1000 mIU/L) can occur due to the stress of venepuncture⁹; hence, it should be repeated in the first instance (perhaps by a cannulated prolactin if available). Drugs that antagonise dopamine, for example, some antipsychotic and antiemetic medications, and non-functioning pituitary adenomas causing ‘disconnection hyperprolactinaemia’, are also common causes of a raised prolactin level, in addition to a prolactin-producing pituitary adenoma (prolactinoma). A prolactin level that is persistently >1000 mIU/L, particularly in the context of amenorrhoea, galactorrhoea, visual field abnormality or headaches warrants referral to endocrinology.⁹ Macroprolactin (presence of a large prolactin aggregate often complexed with an immunoglobulin that has decreased bioactivity) that causes a benign elevation in serum prolactin due

to assay interference should be excluded in all patients with a raised prolactin level.

Most women will undergo menopause between the ages of 45 and 55 years old.¹⁰ Only 1% of women undergo menopause before the age of 40 years and thus if this occurs, this is termed ‘premature’.¹⁰ In women under 40 years of age, a serum follicle stimulating hormone (FSH) level >25 IU/L on two occasions at least 4 weeks apart indicates POI.¹¹ The clinical course of POI is more variable than following the natural menopause with up to 20% of women conceiving spontaneously and hence this condition is termed ovarian ‘insufficiency’ rather than the previously used ‘failure’.¹¹ The cause of POI will require further investigation, as well as exclusion of possible autoimmune, or hereditary predispositions for example, Fragile X syndrome premutations.¹¹ Thus, women with POI should be referred to a specialist service for further investigation of aetiology, to discuss prognosis, as well as to ensure appropriate management to prevent osteoporosis.¹¹

Cushing’s syndrome is a rare cause of menstrual disturbance with hyperandrogenism and weight gain, but if clinically suspected (reddish purple striae, plethora, proximal muscle weakness, bruising with no obvious trauma and unexplained osteoporosis),¹² referral to an endocrinologist for further assessment is recommended. Overt thyroid dysfunction can lead to menstrual and ovulatory disturbance with associated subfertility¹³; however, NICE recommends only testing thyroid function in women with symptoms of thyroid disease.¹

Ovarian reserve testing

The female partner’s age hugely impacts both the chance of subfertility and the response to treatment. Ovarian reserve reflects the number of oocytes remaining within the ovaries and serves as an estimate of a woman’s fertility potential. However, markers of ovarian reserve often do not predict fertility-related clinical outcomes such as ‘time to conception’ or ‘time to menopause’, more accurately than age alone.¹⁴ Thus, measurement of ovarian reserve markers as part of a routine health-screen for fertility disturbance is not advocated. Ovarian reserve markers do correspond to the follicle pool capable of responding to gonadotrophin stimulation during assisted reproduction, and thus can be used to predict the number of oocytes retrieved during in vitro fertilisation (IVF) treatment. Hence, measurement of ovarian reserve markers prior to IVF treatment is indicated to

ensure that appropriate dosing of gonadotrophins to manage the risk of over-response (potentially leading to ovarian hyperstimulation syndrome; OHSS), and of under-response (leading to insufficient follicular growth).

Total antral follicle count (AFC) on ultrasound (US; number of small antral follicles 2–10 mm) measured during the follicular phase, or serum anti-Müllerian hormone (AMH) levels can serve as useful markers of ovarian reserve. Serum AMH and total AFC correlate well to each other and thus either value can be used, although both are prone to measurement error for technical reasons. Serum AMH levels fluctuate only minimally across phases of the menstrual cycle and thus can be measured at any time, whereas AFC is best measured during the follicular phase. Assays for serum AMH have progressed over recent years to become more reliable. Currently, an international standard for AMH has yet to be agreed and different assays report different values. Thus, guidance from the local pathology service is required when interpreting AMH values.¹⁵ However, NICE recommend that <5.4 pmol/L (Beckman Coulter generation II assay) is predictive for a low response during IVF treatment and >25.0 pmol/L a high response.¹ Similarly, a total AFC <4 is suggestive of a predicted reduced response and >16 an increased risk of hyper-response during IVF treatment. Serum AMH levels are also increased in PCOS and they are likely to form part of future criteria for diagnosis of PCOS,¹⁶ although their measurement for this indication is not currently recommended.⁴

A raised serum FSH (>8.9 IU/L) during the early follicular phase is reflective of reduced ovarian reserve, although it is a relatively late feature.¹ NICE recommends against using ovarian volume, ovarian blood flow, serum inhibin B or oestradiol as predictors of any outcome of fertility treatment.¹

Gonadal function estimation in men with abnormal semen analysis

In males, the following blood tests should be requested to evaluate testicular function following two abnormal semen analysis results: fasting testosterone before 10 am (testosterone can fall physiologically during the afternoon and in response to a glucose load,¹⁷ LH, FSH, albumin and SHBG. Testosterone should be measured using equilibrium dialysis method if available, or free testosterone can be calculated using albumin and SHBG in patients with borderline testosterone values).^{18,19} Testosterone levels can vary from day to day and thus at least two measurements are required to diagnose hypogonadism based on a low testosterone level.¹⁹ Hypogonadotrophic hypogonadism (low serum testosterone <9.2 nmol/L with low or inappropriately normal FSH/LH) should prompt referral to an endocrinologist to exclude hypopituitarism. Iron studies (serum ferritin, transferrin saturation) should be performed as an initial screening test for haemochromatosis in patients with hypogonadism.

LH acts on Leydig cells to produce testosterone, which, in turn, negatively feeds back on LH secretion. FSH stimulates testicular Sertoli cells for spermatogenesis, which, in turn, produce inhibin B to negatively feedback on FSH secretion. Thus, a raised FSH level (>7.6 IU/L) in the context of hypogonadism is suggestive of primary gonadal failure; however, FSH levels can be normal in up to 40% of men with impaired spermatogenesis.

Karyotyping

Karyotyping should be performed in women with ambiguous genitalia, or evidence of primary ovarian insufficiency, or clinical features suggestive of Turner syndrome (45×0). In men with

testicular failure of unknown aetiology, a karyotype should be obtained to identify Klinefelter syndrome (47 XXY).

Microbiology

Chlamydia trachomatis²⁰ and gonorrhoea are frequent causes of tubal subfertility. Each episode of acute pelvic inflammatory disease causes subfertility in 10%–15% of cases. A positive test should prompt both partners to be treated. HIV and hepatitis B and C status should also be determined before the use of assisted reproduction.

Imaging

A transvaginal US provides information on uterine/ovarian anatomy, ovarian morphology and ovarian reserve (total AFC).⁴ Access to the ovaries for transvaginal surgical retrieval of oocytes following controlled ovarian stimulation during IVF treatment can be confirmed. Tubal patency should be assessed in women with confirmed ovulation and partners with normal semen analysis by either hysterosalpingography (HSG), hystero-contrast sonography (HyCoSy) or by 'laparoscopy and dye' test. HSG offers a robust assessment of tubal patency; however, HyCoSy has the advantage of avoiding radiation exposure. Laparoscopy is an invasive test, but can be indicated to identify the presence of other pelvic pathology such as endometriosis.²¹

In males with azoospermia and normal testosterone and gonadotrophin levels, a scrotal US scan should be performed to exclude obstructive causes of male subfertility. Men with isolated congenital bilateral absence of vas deferens, frequently (~80%) have mutations in the cystic fibrosis transmembrane conductance regulator gene.²²

Figures 1 and 2 summarise the investigations of male and female subfertility, respectively.

MANAGEMENT OF BOTH PARTNERS

Alcohol

Alcohol consumption should be restricted to ≤ 4 units per week for women and ≤ 3 units per day for men; however, it should be noted the Department for Health Chief Officers' guideline advise that the preferred approach is to not drink alcohol at all if planning conception.²³

Smoking

Smoking has been shown to reduce female fertility^{24,25}; therefore, women should be offered referral to a smoking cessation service.¹ There is also an association between smoking and reduced semen quality in men,²⁶ although the impact of smoking on male fertility remains uncertain.

Drugs

A number of prescription, over-the-counter and recreational drugs interfere with fertility and thus consideration should be given to minimising as many of these as possible.^{27,28}

Tight-fitting underwear

There is an association between elevated scrotal temperature and reduced semen quality^{29,30}; however, it is unclear whether wearing loose-fitting underwear improves fertility.³¹

Body mass index

Men and women with a BMI $>30 \text{ kg/m}^2$ should be advised that losing weight is likely to increase their chance of conception.^{32–36} Women with a BMI $<19 \text{ kg/m}^2$ with oligo/amenorrhoea should be advised that increasing body weight is likely to improve their

Figure 1 Algorithm for evaluation of male subfertility

chance of conception.¹ Women with HA and a BMI <18.5 kg/m² have an increased risk of foetal loss, small-for-gestational-age babies and preterm labour during pregnancy, and thus should be encouraged to gain weight prior to ovulation induction.³⁷

Timing of intercourse

The majority of pregnancies can be attributed to sexual intercourse occurring from 6 days before and including the day of ovulation,^{38,39} with the highest estimated conception rates occurring 2 days before ovulation.⁴⁰ However, timed intercourse can be emotionally stressful,⁴¹ and ovulation can be difficult to predict,³⁸ and thus is not routinely advised.¹ Consequently, couples should be advised that regular sexual intercourse two to three times a week optimises the chance of pregnancy as spermatozoa survive in the female reproductive tract for up to 7 days after insemination.¹ However, couples experiencing difficulties with intercourse every 2–3 days, or those using artificial insemination may benefit from the use of ovulation prediction kits.⁴²

Folic acid supplementation

Women trying to conceive should take dietary supplementation with folic acid 400 µg daily up to 12 weeks of gestation to reduce the risk of foetal neural tube defects (5 mg daily if she has diabetes or is taking antiepileptic medications).¹

MANAGEMENT OF FEMALE SUBFERTILITY

The WHO classifies ovulation disorders into three groups¹

- ▶ **Group I:** hypothalamic pituitary failure (eg, HA, hypogonadotrophic hypogonadism or hyperprolactinaemia)
- ▶ **Group II:** hypothalamic–pituitary–ovarian dysfunction (eg, PCOS)
- ▶ **Group III:** ovarian insufficiency (eg, age-related or POI)

Who group I: hypogonadotrophic hypogonadism

If a woman is not ovulating due to HA, then advice on ensuring adequate energy availability for fertility (by avoiding excessive exercise and having adequate energy intake to achieve a BMI >19 kg/m²) can be recommended in the first instance.³⁷ Cognitive behavioural therapy offers an option to restore ovulation and fertility without pharmaceutical treatment.³⁷ Provided that her BMI is ≥18.5 kg/m², and lifestyle advice has been trialled, then ovulation induction with pulsatile GnRH therapy (if available), or low-dose gonadotrophins, for example with menotrophin can be attempted.³⁷ Women with hyperprolactinaemia should be offered treatment with a dopamine agonist, for example, cabergoline. Women with primary amenorrhoea and lacking pubertal development may have congenital hypogonadotrophic hypogonadism (CHH). In these women, anosmia should be formally assessed with the University of Pennsylvania Smell Test to assess

Figure 2 Algorithm for evaluation of female subfertility

for evidence of Kallmann syndrome, which can be treated with gonadotrophins to induce ovulation.⁴³

Who group II: normogonadotrophic hypogonadism

PCOS is the most common cause of normogonadotrophic hypogonadism with a relatively unchanged FSH level, often accompanied by a raised serum LH level (consistent with increased GnRH pulsatility). If overweight, weight loss of even modest amounts (5%–10%) can improve rates of ovulation and should be encouraged. Ovulation can be restored using clomifene citrate, a selective oestrogen receptor modulator, which reduces oestradiol-induced negative feedback and thus increases FSH levels. US monitoring for at least the first cycle is indicated to reduce the risk of multi-follicular growth and multiple pregnancy. If unsuccessful after six cycles, then IVF treatment can be considered. Although off-label for many years due to unfounded concerns of congenital birth defects, letrozole, an aromatase inhibitor, is an effective option for ovulation induction in PCOS.⁴⁴ Metformin can also be used as an adjuvant to aid in the metabolic dysfunction associated with PCOS.⁴

Who group III: ovarian insufficiency

For women with POI, spontaneous pregnancy can still occur; however, the response to ovarian stimulation as part of IVF

treatment is likely to be very poor. Thus, oocyte donation can be considered as an alternative option.

Tubal / Uterine subfertility

Tubal subfertility can be referred for surgical tubal reconstruction if mild, but otherwise can be bypassed with IVF treatment. Hydrosalpinx can reduce live birth rates during IVF treatment and should be treated laparoscopically prior to commencing treatment. Endometriosis can cause intra-abdominal inflammation and scar tissue and can lead to anatomical obstruction of the fallopian tubes. It may also cause subfertility by producing cytokines that may be toxic to sperm or embryos.⁴⁵ For women seeking fertility, surgical excision or ablation plus adhesiolysis for endometriosis not involving the bowel, bladder or ureter, improves the chance of spontaneous pregnancy.⁴⁶ If the woman has fibroids, a myomectomy may be required to aid fertility, but fibroid embolisation is not recommended.⁴⁷

MANAGEMENT OF MALE SUBFERTILITY

Hypogonadotrophic hypogonadism

In men with hypogonadotrophic hypogonadism, the prognosis is altered by whether previous testicular exposure to FSH has occurred. Patients with CHH have not undergone the 'mini-puberty' that normally occurs during the early neonatal

period. Thus, these patients can have very small volume testes, near undetectable serum inhibin B levels and an increased risk of cryptorchidism.⁴⁸ These men may benefit from an initial period of isolated FSH administration to improve the success of subsequent induction of spermatogenesis.⁴⁸ For most men with acquired or partial hypogonadism (testicular volume >4 mL), spermatogenesis can be restored by providing LH-like exposure to increase intra-testicular testosterone levels. This is often achieved using subcutaneous human chorionic gonadotropin (hCG) given twice weekly for 6 months. Thereafter, a repeat semen analysis is performed to assess response, although response can take up to 2 years. Serum testosterone is monitored every 8 weeks and the dose halved if levels exceed 30 nmol/L. If the man remains azoospermic, human menopausal gonadotrophin (which has both LH and FSH activities) can be added. Combination treatment can then be continued for further 18 months. FSH should induce an increase in testicular volume to the adult range (≥ 15 mL) bilaterally over the course of a year. If sperm is insufficient for either *in vivo* fertilisation or IVF, then sperm banking and intracytoplasmic sperm injection (ICSI) can be used. Obstructive azoospermia (the cause of azoospermia in up to a fifth of men) is less common than non-obstructive azoospermia. The success of ICSI is reduced when using sperm from men with non-obstructive azoospermia when compared with that from men with obstructive azoospermia or freshly ejaculated sperm.

In men who use exogenous anabolic-androgenic steroids, negative feedback on the hypothalamic–pituitary–testicular axis can occur, with a subsequent reduction in intra-testicular testosterone concentration.⁴⁹ This, in turn, can lead to azoospermia, testicular atrophy and hypogonadotrophic hypogonadism.⁵⁰ Recovery of sperm count from azoospermia occurs by 6 months following cessation of exogenous steroid use in approximately two-thirds of men.⁵¹

Primary testicular failure

The most common congenital form of primary testicular failure is Klinefelter syndrome (47 XXY). Men with Klinefelter syndrome can require lifelong androgen replacement and fertility can be supported using ICSI. Other causes include cryptorchidism (75% of males with bilateral cryptorchidism are subfertile), orchitis secondary to mumps or HIV, testicular trauma and following chemotherapy or radiotherapy. It is important not to treat men, who are seeking fertility and have mild hypogonadism plus reduced sperm concentrations with testosterone replacement therapy, as this could reduce endogenous serum gonadotrophin levels (due to testosterone-induced negative feedback) and thus further reduce spermatogenesis. Gonadotrophins are essential to maintain the high intra-testicular testosterone levels required to support spermatogenesis.

Idiopathic semen abnormalities

In obstructive azoospermia, microsurgery can lead to successful pregnancies in up to 25% of couples within 18 months of treatment. During surgery, sperm is retrieved and stored for possible ICSI. Treatment of varicocele is uncertain; however, the evidence indicates no benefit to fertility from varicocele treatment in subfertile men who have normal semen analysis, or in those with subclinical varicocele. Thus, a varicocele repair should only be considered if there is clinically apparent varicocele, with oligospermia, subfertility duration of over 2 years and no other cause of subfertility identified.⁵² Men with very low

sperm concentrations (<5 million) should be tested for Y chromosome microdeletions.

Unexplained subfertility

Unexplained fertility is defined as subfertility despite normal sexual intercourse occurring at least twice weekly, with normal semen analysis, evidence of ovulation in several cycles, normal uterine cavity and normal patent fallopian tubes demonstrated on laparoscopy. Women with unexplained subfertility should be offered IVF treatment after 2 years of trying to conceive, in preference to ovulation induction with clomifene citrate.

Assisted reproductive techniques

Prior to commencing treatment, initial screening includes testing both partners for HIV, hepatitis B, hepatitis C, and, if indicated, thalassaemia and sickle cell.¹

Intrauterine insemination (IUI)

Intrauterine insemination involves the injection of washed and prepared sperm into the uterine cavity through a catheter around the time of ovulation (either spontaneous or induced by hormonal treatments). It is indicated for couples who have barriers to vaginal intercourse (either due to a physical disability or a psychosexual problem), or following sperm washing where the man is HIV positive, or for couples in same-sex relationships using donor sperm. Over half of women aged under 40 years will conceive within 6 cycles of IUI and 75% within 12 cycles. Ovulation induction (hormonal induction of ovarian follicular growth) may improve success rates but is associated with an increased risk of multiple pregnancy.

In vitro fertilisation (IVF)

Ovarian stimulation to induce growth of multiple follicles with US monitoring of the ovarian response to exogenous FSH is the first step in IVF treatment. Following controlled ovarian stimulation, oocytes are retrieved under US guidance and fertilised with sperm *in vitro*. The embryos are then incubated for 3–5 days, before the strongest embryo is selected for transfer into the uterine cavity. Remaining high-quality embryos can be cryopreserved for transfer in subsequent cycles. Luteal phase support in the form of progesterone supplementation is administered at least until confirmation of pregnancy to improve the chance of implantation. Women aged under 40 years who have had 2 years of regular unprotected intercourse should be offered up to three cycles of IVF treatment. Women aged 40–42 years should be offered one cycle of IVF treatment, provided that they do not have evidence of low ovarian reserve. On average, approximately one-quarter of all IVF treatment cycles result in a live birth.⁵³ The chance of success reduces with increasing age of the female partner. The human fertilisation and embryology authority has issued guidance to discourage the use of multiple embryo transfers, which has been a successful strategy causing rates of multiple pregnancy to decline.⁵⁴

Intracytoplasmic sperm injection

ICSI is predominantly reserved for the treatment of ‘male factor’ subfertility, as only a single spermatozoon of normal appearance is required to fertilise the oocyte. A viable spermatozoon is extracted from the sample and injected directly into the oocyte. ICSI is thus more labour-intensive but can be indicated in men with low sperm counts, or in couples where fertilisation was poor in a previous IVF cycle.

Donor insemination

Donor insemination may be considered in azoospermia (not amenable to treatments), where there is a high risk of transmitting a genetic disorder (if pre-implantation genetic diagnosis (PGD) is not possible), or infection, or in the case of severe rhesus isoimmunisation.

Oocyte donation

Conditions where oocyte donation may be appropriate include the following: POI, gonadal dysgenesis, bilateral oophorectomy, or cases where there is a high risk of transmitting a genetic disorder to the offspring (if PGD is not possible).

Complications of assisted reproductive technology (ART)

The most serious complication of IVF treatment is OHSS.⁵⁵ Women with a high serum AMH level, high AFC or polycystic ovary morphology are at particularly increased risk of ovarian hyper-response and OHSS. OHSS occurs predominantly due to the use of hCG to 'mature' oocytes in preparation for retrieval. It results in leakage of fluid into the third spaces of the body, manifesting as lower abdominal discomfort, nausea, vomiting, ascites and pleural effusions. It can result in the need for organ support on the intensive care unit and rarely even mortality. Recently, kisspeptin has been used in place of hCG to avoid the occurrence of OHSS even in women at increased risk.⁵⁶ The use of elective single embryo transfer has helped reduced the risks associated with multiple pregnancy.

CONCLUSION

Subfertility can inflict significant psychological morbidity on affected couples and sensitive expert management is necessary to support such couples. For most couples, reduced fertility is not absolute; the diagnosis represents a reduced chance of conception rather than a complete inability to conceive. Thus, adequate time to conceive must be allowed before a delay in conception is medicalised. However, care must also be taken to ensure that those with very impaired chance of conception with expectant management have prompt access to investigation and fertility treatment. The initial evaluation is to ensure the female partner is ovulating, normal uterine cavity and has patent fallopian tubes, whereas the male partner has normal sperm parameters. In the absence of these, subfertility is termed 'unexplained', although for many couples more than one cause of subfertility may coexist. The female partner's age has a dominant impact on the success of treatment for subfertility. Overall, the prognosis is promising, but multiple treatment cycles may be required before a successful conception is achieved.

Correction notice This article has been corrected since it was published Online First. Provenance and peer review statement was changed to "Commissioned; externally peer reviewed".

Handling editor Tahir S Pillay.

Contributors LT, AA and Professor WD contributed to the writing of the manuscript.

Funding LT is funded by an NIHR Academic Clinical Fellowship. AA is funded by an NIHR Clinician Scientist Award. WSD is funded by an NIHR Research Professorship. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The Section of Endocrinology and Investigative Medicine is funded by grants from the MRC, BBSRC, NIHR, an Integrative Mammalian Biology (IMB) Capacity Building Award, an FP7- HEALTH-2009- 241592 EuroCHIP grant and is supported by the NIHR Biomedical Research Centre Funding Scheme.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; externally peer reviewed

REFERENCES

- 1 National Institute for Health and Care Excellence (NICE). Fertility problems: assessment and treatment. *Clinical guideline* 2013.
- 2 te Velde ER, Eijkemans R, Habbema HDF. Variation in couple fecundity and time to pregnancy, an essential concept in human reproduction. *The Lancet* 2000;355:1928–9.
- 3 Stamou MI, Georgopoulos NA. Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism. *Metabolism* 2018;86:124–34.
- 4 Teede HJ, Misso ML, Costello MF, et al. Recommendations from the International evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Clin Endocrinol* 2018;89:251–68.
- 5 FERRIMAN D, GALLWEY JD. Clinical assessment of body hair growth in women. *J Clin Endocrinol Metab* 1961;21:1440–7.
- 6 Leiva R, Bouchard T, Boehringer H, et al. Random serum progesterone threshold to confirm ovulation. *Steroids* 2015;101:125–9.
- 7 Abbara A, Clarke SA, Nesbitt A, et al. Interpretation of serum gonadotropin levels in hyperprolactinaemia. *Neuroendocrinology* 2018;107:105–13.
- 8 Sassin JF, Frantz AG, Weitzman ED, et al. Human prolactin: 24-hour pattern with increased release during sleep. *Science* 1972;177:1205–7.
- 9 Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011;96:273–88.
- 10 NICE. Overview | menopause: diagnosis and management | guidance | NICE.
- 11 Webber Let al. ESHRE guideline: management of women with premature ovarian insufficiency the ESHRE guideline group on POI. *Hum Reprod* 2016;31:926–37.
- 12 Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing's syndrome: an endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2008;93:1526–40.
- 13 Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid* 2017;27:315–89.
- 14 Steiner AZ, Pritchard D, Stanczyk FZ, et al. Association between biomarkers of ovarian reserve and infertility among older women of reproductive age. *JAMA* 2017;318.
- 15 Magnusson Å, Oleröd G, Thurin-Kjellberg A, et al. The correlation between AMH assays differs depending on actual AMH levels. *Hum Reprod Open* 2017;2017.
- 16 Iliodromiti S, Kelsey TW, Anderson RA, et al. Can anti-Müllerian hormone predict the diagnosis of polycystic ovary syndrome? A Systematic Review and Meta-Analysis of Extracted Data 2013.
- 17 Caronia LM, Dwyer AA, Hayden D, et al. Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism. *Clin Endocrinol* 2013;78:291–6.
- 18 Sartorius G, Ly LP, Sikaris K, et al. Predictive accuracy and sources of variability in calculated free testosterone estimates. *Ann Clin Biochem* 2009;46:137–43.
- 19 Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2010;95:2536–59.
- 20 Haggerty CL, Ness RB. Epidemiology, pathogenesis and treatment of pelvic inflammatory disease. *Expert Rev Anti Infect Ther* 2006;4:235–47.
- 21 Panchal S, Nagori C. Imaging techniques for assessment of tubal status. *J Hum Reprod Sci* 2014;7:2–12.
- 22 Shefi S, Turek PJ. Definition and current evaluation of subfertile men. *Int Braz J Urol* 2006;32:385–97.
- 23 Department of Health. *Alcohol Guidelines Review-Report from the Guidelines development group to the UK Chief Medical Officers with the consultation on the language and understanding of the UK Chief Medical Officers low-risk alcohol guidelines*. 2016.
- 24 Augood C, Duckitt K, Templeton AA. Smoking and female infertility: a systematic review and meta-analysis. *Hum Reprod* 1998;13:1532–9.
- 25 Wesselink AK, Hatch EE, Rothman KJ, et al. Prospective study of cigarette smoking and fecundability. *Hum Reprod* 2019;34:558–67.
- 26 Sharma R, Harlev A, Agarwal A, et al. Cigarette smoking and semen quality: a new meta-analysis examining the effect of the 2010 World Health organization laboratory methods for the examination of human semen. *Eur Urol* 2016;70:635–45.
- 27 Silva PD, Cool JL, Olson KL. Impact of lifestyle choices on female infertility. *J Reprod Med* 1999;44:288–96.
- 28 Sansone A, Di Dato C, de Angelis C, et al. Smoke, alcohol and drug addiction and male fertility. *Reprod Biol Endocrinol* 2018;16.
- 29 Hjøllund NHI, Storgaard L, Ernst E, et al. Impact of diurnal scrotal temperature on semen quality. *Reprod Toxicol* 2002;16:215–21.
- 30 Hjøllund NHI, Bonde JPE, Jensen TK, et al. Diurnal scrotal skin temperature and semen quality. *Int J Androl* 2000;23:309–18.
- 31 Tiemessen CJ, Evers JH, Bots RGM. Tight-fitting underwear and sperm quality. *The Lancet* 1996;347:1844–5.
- 32 Grodstein F, Goldman MB, Cramer DW. Body mass index and ovulatory infertility. *Epidemiology* 1994;5:247–50.

- 33 Bolúmar F, Olsen J, Rebagliato M, *et al.* Body mass index and delayed conception: a European multicenter study on infertility and Subfecundity. *Am J Epidemiol* 2000;151:1072–9.
- 34 Guzick DS, Wing R, Smith D, *et al.* Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. *Fertil Steril* 1994;61:598–604.
- 35 Alshahrani S, Ahmed A-F, Gabr AH, *et al.* The impact of body mass index on semen parameters in infertile men. *Andrologia* 2016;48:1125–9.
- 36 Hayden RP, Flannigan R, Schlegel PN. The role of lifestyle in male infertility: diet, physical activity, and body habitus. *Curr Urol Rep* 2018;19:56.
- 37 Gordon CM, Ackerman KE, Berga SL, *et al.* Functional hypothalamic amenorrhea: an endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2017;102:1413–39.
- 38 Wilcox AJ, Dunson D, Baird DD. The timing of the "fertile window" in the menstrual cycle: day specific estimates from a prospective study. *BMJ* 2000;321:1259–62.
- 39 Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. *N Engl J Med* 1995;333:1517–21.
- 40 Dunson DB, Baird DD, Wilcox AJ, *et al.* Day-specific probabilities of clinical pregnancy based on two studies with imperfect measures of ovulation. *Hum Reprod* 1999;14:1835–9.
- 41 Kopitzke EJ, Berg BJ, Wilson JF, *et al.* Physical and emotional stress associated with components of the infertility investigation: perspectives of professionals and patients. *Fertil Steril* 1991;55:1137–43.
- 42 Cantineau AEP, Janssen MJ, Cohen BJ, *et al.* Synchronised approach for intrauterine insemination in subfertile couples. *Cochrane Database Syst Rev* 2014;15.
- 43 Doty RL, Shaman P, Kimmelman CP, *et al.* University of Pennsylvania smell identification test: a rapid quantitative olfactory function test for the clinic. *Laryngoscope* 1984;94:176–8.
- 44 Kar S. Current evidence supporting "letrozole" for ovulation induction. *J Hum Reprod Sci* 2013;6:93.
- 45 Gupta S, Goldberg JM, Aziz N, *et al.* Pathogenic mechanisms in endometriosis-associated infertility. *Fertil Steril* 2008;90:247–57.
- 46 Endometriosis. *Diagnosis and endometriosis: diagnosis and management management NICE guideline*, 2017.
- 47 Royal College of Obstetricians and Gynaecologists. Clinical recommendations on the use of uterine artery embolisation (UAE) in the management of fibroids. *R. Coll. Radiol* 2013.
- 48 Dwyer AA, Sykiotis GP, Hayes FJ, *et al.* Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. *J Clin Endocrinol Metab* 2013;98:E1790–95.
- 49 Fronczak CM, Kim ED, Barqawi AB. The insults of illicit drug use on male fertility. *J Androl* 2012;33:515–28.
- 50 Schürmeyer T, Belkien L, Knuth UA, *et al.* Reversible azoospermia induced by the anabolic steroid 19-nortestosterone. *The Lancet* 1984;323:417–20.
- 51 Tatem AJ, Beilan J, Kovac JR, *et al.* Management of anabolic steroid-induced infertility: novel strategies for fertility maintenance and recovery. *World J Mens Health* 2019;37.
- 52 Jungwirth A, Giwercman A, Tournaye H, *et al.* European association of urology guidelines on male infertility: the 2012 update. *Eur Urol* 2012;62:324–32.
- 53 Human fertilisation and embryology authority. *Fertility Treatment in 2013*, 2013.
- 54 HFEA. *Improving outcomes for fertility patients : Multiple births*. London EC1Y 8HF: HFEA, 2011.
- 55 Marzal A, Holzer H, Tulandi T. Future developments to minimize art risks. *Semin Reprod Med* 2012;30:152–60.
- 56 Jayasena CN, Abbara A, Comninou AN, *et al.* Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. *J Clin Invest* 2014;124:3667–77.
- 57 Cooper TG, Noonan E, von Eckardstein S, *et al.* World Health organization reference values for human semen characteristics. *Hum Reprod Update* 2010;16:231–45.